InvestorsHub Logo
Followers 5
Posts 280
Boards Moderated 0
Alias Born 08/29/2015

Re: XenaLives post# 88400

Saturday, 01/21/2017 3:16:49 PM

Saturday, January 21, 2017 3:16:49 PM

Post# of 459521
Great article. Thanks for posting.
A discussion broke out the other day about why big pharma has continued to go down the wrong path and why I think Anavex is continuing to advance towards approval.
My thought was that BP has put so much money, time, effort into their research, that they are having a hard time pivoting from
their group think of the original hypothesis. They continue to try to parse data to find the subgroup that shows results. If I were a shareholder of those companies I would consider a class action lawsuit for malfeasance of fiscal responsibility. Multiple failed trails is no
way to manage shareholders money. Where are the multiple firms jumping on these guys the way they piled on us last year?
I submit that Anavex is checking all the boxes, submitting data to scientific review, showing results that are beyond expections confirmed by third party research organizations. Developing a team of advisers with distinguished backgrounds in relevant fields.
Some insight into our stealthy company, Fidelity has a risk/reward assessment for Avxl and it is point one, not even above 1.
When asked why this is so low, and how could they be so far from seeing the value, I have to say they just aren't doing their homework.
And to those people I say please,please,please short some more.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News